Objective: To investigate the pediatric group expression of β-catenin and pattern of immunohistochemistry in medulloblastoma patients following WHO classification.
Study Design: Cross-sectional descriptive study.
Place and Duration of Study: Current study designed and conducted in Department of Histopathology, Shaukat Khanum Hospital Memorial Cancer Hospital and Research Canter, Lahore. All cases of medulloblastoma (1 year -15 year) were retrieved from a computerized database diagnosed between 2015-2017 year.
Material and Methods: Electronic hospital information system was used to select medulloblastoma patients. Results were categorized to see the frequency in all cases. Beta-catenin and other immune-histochemical staining pattern were observed among different molecular types. Nuclear positivity of beta-catenin was considered as a positive result.
Results: Sixty diagnosed cases of Medulloblastoma were retrieved from the records. Mean age of the patients was 4.68 ± 3.62 years. There were n=41 (68%) males as compared to n=19 (32%) females. SHH pathway active- tion was the most common abnormality seen in n=39 (65%) of the patients followed by Non-SHH pathway medulloblastomas n=19 (32%). Only one case (1.6%) was found with positive expression of beta-catenin. Major expression of immune-histochemical stain was Synaptophysin positive in 56 (94%) cases.
Conclusion: Molecular classification helps to stratify these patients according to their biological aggressiveness and aid clinicians to better plan treatment strategies. Beta-Catenin nuclear expression leads activation of Wnt Pathway which is associated with better prognosis and is nowadays treated with therapy de-escalation. However, our study has shown that our population has an extremely small number of patients with this phenotype.
Keywords : Beta-Catenin, Medulloblastoma, Molecular Classification, WHO, Wnt-Pathway.